Keyphrases
Chronic Lymphocytic Leukemia
100%
Mantle Cell Lymphoma
77%
Ibrutinib
28%
Lymphoma
21%
Minimal Residual Disease
18%
Stereotyped B-cell Receptors
18%
TP53 mutation
18%
Lymphoma Patients
17%
Relapsed or Refractory
17%
Immunogenetics
16%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
16%
Tumor Protein p53 (TP53)
16%
Lenalidomide
16%
Rituximab
15%
Stereotyped Subsets
15%
Phase II Study
14%
Programmed Death-ligand 1 (PD-L1)
14%
Poor Prognostic
14%
Phase II Trial
14%
B Cell Receptor
13%
Leukemia Patients
13%
TP53 Aberrations
13%
Immunoglobulin
12%
Progression-free Survival
11%
Complete Remission
9%
Overall Survival
9%
BIRC3
9%
SF3B1
9%
Bendamustine-rituximab
9%
IGHV4-34
9%
Chemoimmunotherapy
8%
Lymphocytosis
8%
Clinical Impact
8%
Notch1
8%
Previously Untreated
8%
Denmark
8%
Molecular Classification
7%
Disease Outcome
7%
Gene mutation
7%
Cytarabine
7%
Somatic Hypermutation
7%
Higher Order Connections
7%
Novel Gene mutation
7%
Molecular Relapse
7%
Practitioner Experiences
7%
Absolute Lymphocyte Count
7%
Deep Targeted Sequencing
7%
Zevalin
7%
Non-complete Remission
7%
Depth of Response
7%
Biochemistry, Genetics and Molecular Biology
B-Cell Receptor
46%
Stereotypy
21%
Intravenous Immunoglobulin
21%
IGHV@
21%
Genetics
19%
Immunogenetics
17%
Gene Mutation
16%
SF3B1
14%
Overall Survival
12%
Somatic Hypermutation
12%
Immunoglobulin
11%
B Cell
11%
Immunoglobulin M
9%
Signal Transduction
8%
Progression Free Survival
8%
Autoantigen
7%
Ibrutinib
7%
MicroRNA
7%
Patient Coding
7%
Stem Cell
7%
PD-L1
7%
Cytarabine
7%
Stem Cell Transplant
7%
Drug Megadose
7%
Rituximab
7%
Multivariate Analysis
7%
Gene Frequency
7%
Event Free Survival
7%
Cytogenetics
6%
Immunoglobulin Gene
6%
Isolated Growth Hormone Deficiency
6%
Medicine and Dentistry
Mantle Cell Lymphoma
49%
B-Cell Chronic Lymphocytic Leukemia
49%
Ibrutinib
28%
Rituximab
20%
Disease
15%
Mantle Cell Lymphoma International Prognostic Index
14%
Arm
14%
B Lymphocyte Receptor
13%
Overall Survival
12%
Autologous Stem Cell Transplantation
11%
Progression Free Survival
9%
Immunoglobulin
9%
Minimal Residual Disease
9%
Lymphocytosis
8%
Chemoimmunotherapy
7%
Stem Cell
7%
Lenalidomide
7%
B-Lymphoblastoid Cell Line
7%
Targeted Therapy
7%
Immunogenetics
7%
Lymphocyte
7%
Cytarabine
6%
microRNA
5%